Drug delivery device

Abstract

To provide medicine releasing equipment using light.SOLUTION: Medicine releasing equipment includes a light source part and a medicine supply part having a medicine irradiated with light from the light source part. The medicine supply part releases or ejects the medicine by the light from the light source part. The light source part may be a laser or a light emitting diode. The surface on which the light is made incident of the medicine supply part may be formed of a material that transmits light, and the surface onto which the medicine of the medicine supply part is released or ejected may be formed of a material selected from a group consisting of a porous material, a high polymer material, a fiber assembly, an osmotic membrane, and a reverse osmotic membrane.SELECTED DRAWING: Figure 1

Description

[Technical field]

[0001] The present invention relates to a drug delivery device. [Background technology]

[0002] In recent years, needle-free syringes that do not use needles have been developed, and it has been reported that they reduce the pain of perforation (see, for example, Patent Document 1). Patent Document 1 discloses a needle-free syringe of the injection type for injecting a medicinal liquid contained in a container through the skin by injecting it from an injection port provided at the tip side of the container, the needle-free syringe having a thermomodule with a heat absorbing part that absorbs heat and a heat dissipating part that dissipates heat, a cooling part that is provided on the heat absorbing part side of the thermomodule near the injection port and for cooling the injection site of the skin, and a heating part that is provided on the heat dissipating part side of the thermomodule and for warming the medicinal liquid in the container. Patent Document 1 reports that the cooling part provided on the heat absorbing part side of the thermomodule near the injection port is brought into contact with the skin, and the skin at the injection site is quickly cooled, thereby paralyzing the nerves concentrated in the dermis layer, and reducing the pain when the medicinal liquid is injected with a simple configuration. However, even if the needleless syringe of Patent Document 1 is used, the drug solution can only be administered to the subcutaneous tissue layer or muscle tissue layer, and cannot be administered to deeper tissues.

[0003] Meanwhile, a treatment method using a laser molecular injection method has been reported (see, for example, Patent Document 2). According to Patent Document 2, organic molecules dispersed or dissolved in a solution present in the hollow part of an optical fiber can be injected into biological tissue, so that photosensitizing molecules can be injected only around the cancer tissue, and the cancer tissue can be destroyed by singlet oxygen generated by the laser light combined with the photosensitizing molecules. However, even with the technology of Patent Document 2, although it is possible to approach the vicinity of internal organ cancer tissue with an optical fiber, it is difficult to inject a drug uniformly into the deep part of the organ.

[0004] Also, a technology using another laser molecular injection method has been reported (see, for example, Patent Document 3). According to Patent Document 3, a method is described in which a molecular injection source containing molecules is irradiated with focused light, thereby injecting the molecules into a substrate placed at least in the traveling direction of the light, and the molecules contained in the molecular injection source are injected into the substrate via a liquid inserted between the molecular injection source and the substrate. Using such a technology, it is possible not only to inject and fix molecules into a minute region of 50 nm or less, but also to process materials. Further industrial applications of such a technology are expected. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] JP 2005-80832 A [Patent Document 2] Patent No. 3621283 [Patent Document 3] Patent No. 5205669 Summary of the Invention [Problem to be solved by the invention]

[0006] SUMMARY OF THE PRESENT EMBODIMENTS In view of the above, an object of the present invention is to provide a drug delivery device that uses light. [Means for solving the problem]

[0007] The drug release device according to the present invention comprises a light source unit and a drug supply unit having a drug that is irradiated with light from the light source unit, and the drug supply unit releases or ejects the drug by the light from the light source unit, thereby solving the above-mentioned problem. The light source unit may be a laser or a light emitting diode. The laser or light emitting diode may be a tunable laser. The drug supply section may be made of a material that transmits the light and further include a container in which the drug is filled, and the surface of the container from which the drug is released or ejected may be made of a material selected from the group consisting of a porous material, a polymeric material, a fiber aggregate, an osmosis membrane, and a reverse osmosis membrane. The light-transmitting material is a material selected from the group consisting of glass, quartz, and sapphire when the light has a wavelength in the visible light region, and may be selected from the group consisting of germanium (Ge), silicon (Si), silicon carbide (SiC), calcium fluoride (CaF2), barium fluoride (BaF2), magnesium fluoride (MgF2), thallium halide mixed crystal, lithium fluoride (LiF), silicon dioxide (SiO2), and zinc selenide (ZnSe) when the light has a wavelength in the infrared region. The medicine supply section may include a reservoir tank that supplies a medicine, and a porous body that holds the medicine supplied from the reservoir tank. The drug may contain a medicinal ingredient selected from the group consisting of immunosuppressants, antirheumatic drugs, gout treatment drugs, diabetes treatment drugs, sex hormone drugs, hormone drugs, bone metabolism improving drugs, cardiac stimulants, antiarrhythmic drugs, antibacterial agents, anticancer drugs, anti-inflammatory drugs, cancer treatment viruses, and photosensitizers. The drug may contain, in addition to the medicinal ingredient, a solvent for dispersing the medicinal ingredient. The solvent may be water, physiological saline, ethanol, acetonitrile, chlorobenzene, chloroform, cyclohexane, 1,2-dichloroethene, dichloromethane, 1,2-dimethoxyethane, N,N-dimethylacetamide, N,N-dimethylformamide, 1,4-dioxane, 2-ethoxyethanol, ethylene glycol, formamide, hexane, methanol, 2-methoxyethanol, methylbutylketone, methylcyclohexane, N-methylpyrrolidone, nitromethane, pyridine, sulfolane, tetralin, toluene, 1,1,2-trichloroethene, xylene, acetic acid, acetone, anisole, butanol, butyl acetate, butyl methyl ether, cumene, At least one of the dimethyl sulfoxide, ethyl acetate, diethyl ether, ethyl formate, formic acid, heptane, isobutyl acetate, isopropyl acetate, methyl acetate, 3-methyl-1-butanol, methyl ethyl ketone, methyl isobutyl ketone, 2-methyl-1-propanol, pentane, 1-pentanol, 1-propanol, 2-propanol, propyl acetate, tetrahydrofuran, 1,1-diethoxypropane, 1,1-dimethoxymethane, 2,2-dimethoxypropane, isooctane, isopropyl ether, methyl isopropyl ketone, methyl tetrahydrofuran, petroleum ether, trichloroacetic acid, and trifluoroacetic acid may be selected from the group consisting of. The light source unit may emit light having photon energy that excites the medicinal ingredient. The drug supply portion may include a drug sheet containing the drug. The drug sheet may contain a medicinal ingredient selected from the group consisting of steroidal anti-inflammatory agents, non-steroidal anti-inflammatory agents, antiallergic agents, antihistamines, central nervous system agents, hormones, antihypertensive agents, cardiac stimulants, antiarrhythmic agents, coronary vasodilators, local anesthetics, analgesics, muscle relaxants, antifungal agents, anti-cancer agents, urinary incontinence agents, antiepileptic agents, anti-Parkinson's agents, antiemetic agents, agents for treating frequent urination, Ca antagonists, psychotropic drugs, antidizziness agents, cardiovascular agents, antitussives and expectorants, agents for improving cerebral circulation, agents for cerebrovascular dementia, agents for treating Alzheimer's, polypeptide hormone agents, immunomodulators, choleretic agents, diuretics, agents for diabetes, agents for treating gout, agents for quitting smoking, vitamins, prostaglandins, stimulants, hypnotics and sedatives, agents for affecting the autonomic nervous system, and peripheral vasodilators. The medicine supply section may further include a transparent sheet made of a material that transmits the light, and the medicine sheet may be laminated on the transparent sheet. The light source unit may further include a control unit for controlling irradiation of light from the light source unit. The control unit may control light irradiation with at least one selected from the group consisting of an irradiation time of the light, an irradiation timing of the light, and a wavelength of the light. The medicine supply unit may be provided detachably with respect to the light source unit. Effect of the Invention

[0008] The drug release device according to the present invention comprises a light source unit and a drug supply unit containing a drug to be irradiated with light from the light source unit, and in the drug supply unit, the medicinal ingredient in the drug absorbs the light and releases or ejects the drug by the light, making it possible to dispense a needle-free device and reduce the burden on the patient. Since shock waves, cavitation bubbles, and molecular vibrations induced by light are used, the medicinal ingredient can be administered almost undecomposed not only to the subcutaneous tissue layer or muscle tissue layer but also to deeper layers. [Brief description of the drawings]

[0009] [Figure 1] Schematic diagram showing a drug delivery device according to the present invention. [Diagram 2] Schematic diagram showing a state of treatment using the drug delivery device according to the present invention. [Diagram 3] FIG. 1 is a schematic diagram showing another drug supply unit according to the present invention. [Figure 4] FIG. 2 is a schematic diagram showing yet another drug delivery device according to the present invention; DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] The drug discharging device of the present invention comprises a light source unit and a drug supply unit that contains a drug to be irradiated with light from the light source unit, and the drug supply unit releases or ejects the drug by the light from the light source unit. Hereinafter, the drug discharging device of the present invention will be specifically described with reference to the drawings. Note that similar elements are given similar numbers and their description will be omitted.

[0011] (Embodiment 1) In the first embodiment, a drug delivery device using a molecular jet and a treatment method using the same will be described. FIG. 1 is a schematic diagram showing a drug delivery device according to the present invention. FIG. 2 is a schematic diagram showing a state of treatment using the drug delivery device according to the present invention.

[0012] The drug release device 100 according to the present invention includes a light source unit 110 and a drug supply unit 120 including a drug 130 that is irradiated with light from the light source unit 110. The drug supply unit 120 further includes a container 121 made of a light-transmitting material and filled with the drug 130, and the surface of the container 121 from which the drug 130 is released or ejected is a drug permeable surface 122 made of a material selected from the group consisting of a porous material, a polymeric material, a fiber aggregate, an osmosis membrane, and a reverse osmosis membrane.

[0013] Each component will be described. The light source unit 110 is not particularly limited as long as it emits light with a wavelength having sufficient photon energy to excite the medicinal ingredient (also called drug molecule) in the drug 130, but it is preferable that it emits a wavelength in the range of 360 nm to 8 μm. The light source unit 110 may be, for example, a laser or a light-emitting diode. These can emit lasers of various wavelengths and are easy to obtain. The laser may be a gas laser, a solid-state laser, a semiconductor laser, or the like.

[0014] Lasers or light emitting diodes may be optically coupled to multiple optical fibers in a bundle, forming multiple point sources of light that can be uniformly illuminated.

[0015] A laser or a light emitting diode may be appropriately combined with an optical system such as a collimator lens, a fly-eye lens, etc. For example, by combining it with a fly-eye lens, a plurality of point light sources are formed, thereby enabling uniform irradiation.

[0016] The laser light may be continuous wave (CW) or pulsed, but is preferably a pulsed laser from the viewpoints of suppressing decomposition of drug molecules and controlling the injection amount.

[0017] The light source unit 110 may include a plurality of lasers or light emitting diodes, or may include a wavelength tunable laser, so that even if there are a plurality of drugs 130, the light required for exciting the drugs 130 can be appropriately selected.

[0018] The container 121 is not particularly limited as long as it transmits light from the light source unit 110, but for example, when the light has a wavelength in the visible light region (range of 360 nm or more and 830 nm or less), the container 121 is made of a material selected from the group consisting of glass, quartz, and sapphire, and when the light has a wavelength in the infrared region (range of more than 830 nm and 8 μm or less), the container 121 is made of a material selected from the group consisting of germanium (Ge), silicon (Si), silicon carbide (SiC), calcium fluoride (CaF2), barium fluoride (BaF2), magnesium fluoride (MgF2), thallium halide mixed crystal, lithium fluoride (LiF), silicon dioxide (SiO2), and zinc selenide (ZnSe).

[0019] The drug 130 filled in the container 121 is not particularly limited as long as it contains a medicinal component that is injected into the body for use, and may be, for example, selected from the group consisting of immunosuppressants, antirheumatic drugs, gout treatment drugs, diabetes treatment drugs, sex hormone drugs, hormone drugs, bone metabolism improving drugs, cardiac stimulants, antiarrhythmic drugs, antibacterial agents, anticancer drugs, anti-inflammatory drugs, cancer treatment viruses, and photosensitizers. Examples of these medicinal components are shown in Table 1. It should be noted that the medicinal components shown in Table 1 are merely examples and are not limited to these. The light wavelength (photon energy) required to excite the medicinal component (drug molecule) can be easily determined, for example, by measuring the absorption spectrum with a spectrophotometer.

[0020] [Table 1]

[0021] The medicine 130 may contain a solvent for dispersing the medicinal ingredient in addition to the medicinal ingredient. Such a solvent should transmit but not absorb the light from the light source unit 110. The transmission wavelength range can be easily determined by measuring the transmission and absorption spectrum of the solvent.

[0022] Examples of the solvent include water, physiological saline, ethanol, acetonitrile, chlorobenzene, chloroform, cyclohexane, 1,2-dichloroethene, dichloromethane, 1,2-dimethoxyethane, N,N-dimethylacetamide, N,N-dimethylformamide, 1,4-dioxane, 2-ethoxyethanol, ethylene glycol, formamide, hexane, methanol, 2-methoxyethanol, methylbutylketone, methylcyclohexane, N-methylpyrrolidone, nitromethane, pyridine, sulfolane, tetralin, toluene, 1,1,2-trichloroethene, xylene, acetic acid, acetone, anisole, butanol, butyl acetate, butyl methyl ether, cumene, ethyl acetate ... The solvent is at least one selected from the group consisting of ethanol, dimethyl sulfoxide, ethyl acetate, diethyl ether, ethyl formate, formic acid, heptane, isobutyl acetate, isopropyl acetate, methyl acetate, 3-methyl-1-butanol, methyl ethyl ketone, methyl isobutyl ketone, 2-methyl-1-propanol, pentane, 1-pentanol, 1-propanol, 2-propanol, propyl acetate, tetrahydrofuran, 1,1-diethoxypropane, 1,1-dimethoxymethane, 2,2-dimethoxypropane, isooctane, isopropyl ether, methyl isopropyl ketone, methyl tetrahydrofuran, petroleum ether, trichloroacetic acid, and trifluoroacetic acid. These solvents can disperse medicinal ingredients, are not taboo when ingested, and are naturally decomposed and excreted.

[0023] Those skilled in the art can appropriately select the wavelength of light from the light source unit 110 and the type of solvent depending on the excitation wavelength of the medicinal ingredient (drug molecule).

[0024] There are no particular limitations on the drug permeable surface 122 of the container 121 as long as it has pores through which a molecular jet 250 (FIG. 2) described below can pass, but it is preferable for the pores to have a diameter of several tens of nm to several tens of μm.

[0025] Porous materials constituting the drug permeable surface 122 include, for example, porous ceramics such as porous alumina, lotus metal, mesoporous silica, and zeolite.

[0026] Examples of polymeric materials include porous polymers containing polyethylene glycol as a main component, polypropylene porous polymers, and polystyrene porous polymers.

[0027] The fiber aggregate may be made of polyester, nylon, cotton, rayon, down, polyvinylidene chloride, cellulose, polypropylene, silicon carbide, spider silk fiber, or the like.

[0028] Examples of the permeation membrane include cellophane, collodion, bladder membrane, acetyl cellulose, polyacrylonitrile, Teflon (registered trademark), polyester polymer alloy, polysulfone, etc. Examples of the reverse osmosis membrane include cellulose acetate membrane, aromatic polyamide, etc. These may be appropriately selected depending on the application.

[0029] Next, with reference to FIG. 2, the mechanism of drug release using the drug release device of FIG. 1 will be described.

[0030] The drug release device 100 in Fig. 1 is applied to a body surface 210, and light 220 is emitted from the light source unit 110 ((a)). As a result, the light 220 is irradiated onto the drug 130 in the container 121, and only the medicinal ingredient in the drug 130 absorbs the light 220 and becomes optically excited. As a result, the excited medicinal ingredient imparts energy to the solvent, generating a shock wave 230 ((b)).

[0031] Then, cavitation bubbles 240 are generated and grow large. When the cavitation bubbles 240 reach their maximum size, they rapidly shrink ((c)). The focused drug is ejected from the center of the shrunken cavitation bubble 240 as a molecular jet 250, and is injected into the body surface 210 through the pores in the drug permeable surface 122 of the drug delivery device 100 ((d)).

[0032] The depth of the molecular jet 250 into the body surface 210 can be adjusted by the wavelength, intensity, time, etc. of the light 220 from the light source unit 110, and depending on the application, injection into the subcutaneous tissue layer, muscle tissue layer, or even deeper layers can be performed without a needle. At this time, the diameter of the molecular jet 250 remains at a size of several tens of nm to several tens of μm, so no scars are left. Furthermore, the drug irradiated with the light 220 in this way is injected without being decomposed.

[0033] Returning to Fig. 1 again, the drug release device 100 of the present invention may further include a control unit (not shown) that controls the irradiation of light from the light source unit 110. The control unit may control the irradiation of at least one light selected from the group consisting of the irradiation time of light from the light source unit 110, the irradiation timing (number of irradiations), and the wavelength of light. This allows control of the injection depth, administration time, etc.

[0034] Furthermore, the drug supply unit 120 may be provided so as to be detachable from the light source unit 110. This allows the drug 130 to be easily replaced and used repeatedly.

[0035] FIG. 3 is a schematic diagram showing another drug supply unit according to the present invention.

[0036] The drug discharging device 300 according to the present invention includes a light source unit 110 and a drug supply unit 120 including a drug 130 to be irradiated with light from the light source unit 110. The drug supply unit 120 further includes a reservoir tank 310 in which the drug 130 is filled and supplied, and a porous body 320 that supplies and holds the drug 130 from the reservoir tank 310. Note that the light source unit 110 and the drug 130 are as described above, and therefore description thereof will be omitted.

[0037] There are no particular limitations on the material, shape, etc. of the reservoir tank 310 as long as it is capable of holding the above-mentioned chemical 130 and the solvent in which the chemical 130 is dispersed, and is connected so as to supply them to the porous body 320 .

[0038] There are no particular limitations on the porous body 320 so long as it can hold the drug 130, but examples include open-cell foams of synthetic resins such as polyurethane, polyethylene, nylon, and melamine, as well as woven fabrics, nonwoven fabrics, and metal fiber assemblies having a three-dimensional skeletal structure consisting of layers such as honeycomb, mesh, and net-like layers.

[0039] 1, when the drug releasing device 300 is applied to the body surface and light is emitted from the light source unit 110, the medicinal ingredient in the drug 130 impregnated in the porous body 320 absorbs the light and becomes excited. The excited medicinal ingredient provides energy to the solvent, generating a shock wave in the porous body 320.

[0040] Next, as cavitation bubbles are generated and grow large, they rapidly shrink, and the focused drug is ejected from the center of the shrunken cavitation bubble as a molecular jet and injected into the body surface through the pores of the porous body 320 of the drug delivery device 300.

[0041] Unlike the drug delivery device 100, the drug delivery device 300 allows for long-term administration since the reservoir tank 310 is filled with the drug 130.

[0042] The drug discharging device 300 may also include a control unit that controls the light emission from the light source unit 110, similar to the drug discharging device 100. Moreover, the drug supply unit 120 may be removable.

[0043] In addition, if there is a risk that the medicinal ingredient (drug molecule) will decompose or change due to absorption of light from the light source unit 110, it is possible to avoid the light absorption wavelength of the medicinal ingredient and directly photoexcite the solvent (multiple solvents can be mixed and separated into those that absorb light and those that do not. In this case, it is possible to control the magnitude of the injection phenomenon by the concentration of the solvent that absorbs light), or to mix non-target drug molecules or photosensitizing molecules into the solvent as auxiliary molecules, and photoexcite them instead of the target drug molecules to generate shock waves and cavitation bubbles, thereby injecting the target drug ingredient together with these auxiliary molecules using a method similar to that described above.

[0044] (Embodiment 2) In the second embodiment, a drug release device utilizing molecular diffusion and a treatment method using the same will be described. FIG. 4 is a schematic diagram showing yet another drug delivery device according to the present invention.

[0045] The drug discharging device 400 according to the present invention includes a light source unit 110 and a drug supply unit 120 to which light from the light source unit 110 is irradiated. The drug supply unit 120 includes a drug sheet 410 containing a medicinal component. In FIG. 4, the drug supply unit 120 is laminated on the drug sheet 410 and further includes a transparent sheet 420 that transmits the light from the light source unit 110, but the transparent sheet 420 may be omitted. The light source unit 110 is as described above and will not be described here.

[0046] The drug sheet 410 is not particularly limited as long as it contains a medicinal ingredient that can be absorbed transdermally, and illustrative examples include an active ingredient selected from the group consisting of steroidal anti-inflammatory agents, non-steroidal anti-inflammatory agents, antiallergic agents, antihistamines, central nervous system agents, hormones, antihypertensive agents, cardiac stimulants, antiarrhythmic agents, coronary vasodilators, local anesthetics, analgesics, muscle relaxants, antifungal agents, anti-malignant tumor agents, urinary incontinence agents, antiepileptic agents, anti-Parkinson's agents, antiemetic agents, frequent urination agents, calcium antagonists, psychotropic drugs, antivertigo agents, cardiovascular system agents, antitussives and expectorants, cerebral circulation improving agents, cerebrovascular dementia agents, Alzheimer's agents, polypeptide hormone agents, immunomodulators, choleretic agents, diuretics, diabetes agents, gout agents, smoking cessation aids, vitamins, prostaglandins, stimulants, hypnotics and sedatives, autonomic nervous system agents, and peripheral vasodilators. Examples of these medicinal ingredients are shown in Table 2. It should be noted that the medicinal ingredients shown in Table 2 are merely examples and are not limited thereto.

[0047] [Table 2]

[0048] In addition to the medicinal component, the drug sheet 410 may contain a moisturizing component, water, a water-soluble polymer, a crosslinking agent, etc. This allows the drug sheet 410 to have adhesiveness that allows it to be attached to the skin.

[0049] Examples of moisturizing components include polyhydric alcohols such as glycerin, diglycerin, polyglycerin, 1,3-butylene glycol, propylene glycol, dipropylene glycol, polyethylene glycol, polypropylene glycol with an average molecular weight exceeding 425, polyoxyethylene glyceryl ether, methyl glucoside, polyoxyethylene methyl glucoside, erythritol, xylitol, sorbitol, mannitol, maltitol, and trehalose, sugar alcohols, sugars, amino acids, and proteins.

[0050] The water functions as a dispersant for the medicinal components, aqueous polymers, moisturizing components, and crosslinking agents, and can be purified water, natural water, sterilized water, or the like.

[0051] The water-soluble polymer may be, for example, gelatin, polyacrylic acid or a salt thereof, or a partially neutralized product thereof.

[0052] Examples of the crosslinking agent include poorly water-soluble aluminum compounds such as aluminum hydroxide, aluminum hydroxide gel, hydrated aluminum silicate, synthetic aluminum silicate, kaolin, aluminum acetate, aluminum lactate, aluminum stearate, magnesium aluminometasilicate, and magnesium aluminosilicate, and polyfunctional epoxy compounds such as polyethylene glycol diglycidyl ether, ethylene glycol diglycidyl ether, glycerin diglycidyl ether, glycerin triglycidyl ether, propylene glycol diglycidyl ether, polyglycerol polyglycidyl ether, sorbitol polyglycidyl ether, sorbitan polyglycidyl ether, trimethylolpropane polyglycidyl ether, pentaerythritol polyglycidyl ether, resorcinol diglycidyl ether, and neopentyl glycol diglycidyl ether.

[0053] The drug sheet 410 may further contain known skin-beautifying ingredients, preservatives, antioxidants, tackifiers, dissolving agents, pigments, fragrances, surfactants, UV absorbers, pH adjusters, oils, and the like.

[0054] Examples of skin-beautifying ingredients include ceramides, vitamins (vitamin A, vitamin B, vitamin C, vitamin D, vitamin E, and their derivatives), hyaluronic acid and its salts, chondroitin sulfate and its salts, tuberose polysaccharides, amino acids and their derivatives and protein hydrolysates, organic acids such as hydroxy acids, glycoproteins such as lactoferrin, ubidecarenone (coenzyme Q10), alpha-lipoic acid (thioctic acid), animal and plant extracts, and urea.

[0055] Examples of preservatives include paraoxybenzoic acid esters, benzoic acid and its salts, sorbic acid and its salts, dehydroacetate, phenol, isopropylmethylphenol, hinokitiol, benzalkonium chloride, benzethonium chloride, and chlorhexidine chloride.

[0056] Examples of the antioxidant include ascorbic acid and its salts, ascorbic acid esters, carotene, astaxanthin, propyl gallate, butylhydroxyanisole, and dibutylhydroxytoluene.

[0057] Examples of tackifiers include casein, pullulan, agar, dextran, sodium alginate, soluble starch, carboxy starch, dextrin, carboxymethyl cellulose, sodium carboxymethyl cellulose, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, polyvinyl alcohol, polyethylene oxide, polyacrylamide, polyacrylic acid, polyvinylpyrrolidone, carboxyvinyl polymer, polyvinyl ether, polymaleic acid copolymer, methoxyethylene maleic anhydride copolymer, isobutylene maleic anhydride copolymer, and polyethyleneimine.

[0058] The dissolving agent may be, for example, a lower alcohol such as ethyl alcohol, propyl alcohol, butyl alcohol, or benzyl alcohol.

[0059] Examples of pigments include Red No. 102 (New Coction), Red No. 104-(1) (Phloxine B), Red No. 105-(1) (Rose Bengal), Red No. 106 (Acid Red), Red No. 2 (Amaranth), Red No. 3 (Erythrosine), Yellow No. 4 (Tartrazine), Yellow No. 5 (Sunset Yellow FCF), Green No. 3 (Fast Green FCF), Blue No. 1 (Brilliant Blue FCF), and Blue No. 2 (Indigo Carmine).

[0060] As the fragrance, fragrances that can be used in the fields of medicines, quasi-drugs, cosmetics, sanitary materials, miscellaneous goods, etc. can be used.

[0061] Examples of the surfactant include anionic surfactants such as sodium dialkyl sulfosuccinate, sodium dodecylbenzenesulfonate, and alkyl alphate salts; cationic surfactants such as hexadecyltrimethylammonium chloride and octadecyldimethylbenzylammonium chloride; nonionic surfactants such as polyoxyethylene stearyl ether, polyoxyethylene octyldodecyl ether, polyoxyethylene nonylphenyl ether, polyoxyethylene octylphenyl ether, polyoxyethylene monostearate, sorbitan monostearate, sorbitan monopalmitate, polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan tetraoleate, glycerin fatty acid esters, polyglycerin fatty acid esters, polyethylene glycol monostearate, polyoxyethylene hydrogenated castor oil, and polyoxyethylene octadecylamine; and amphoteric surfactants such as stearyl betaine and lauryl dimethylamine oxide.

[0062] Examples of ultraviolet absorbents include para-aminobenzoic acid and its esters, amyl para-dimethylaminobenzoate, oxybenzone, tetrahydroxybenzophenone, hydroxymethoxybenzophenone sulfonic acid, and cinoxate.

[0063] Examples of pH adjusters include tartaric acid, succinic acid, citric acid, lactic acid, malic acid, acetic acid, glycolic acid, hydrochloric acid, oxalic acid, phosphoric acid, sodium hydroxide, potassium hydroxide, methylamine, dimethylamine, trimethylamine, ethylamine, diethylamine, triethylamine, propylamine, dipropylamine, tripropylamine, monomethanolamine, dimethanolamine, trimethanolamine, monoethanolamine, diethanolamine, triethanolamine, monopropanolamine, dipropanolamine, tripropanolamine, citrates, phosphates, and carbonates.

[0064] Examples of oils include vegetable oils such as jojoba oil, olive oil, avocado oil, peppermint oil, camellia oil, and grape seed oil; animal oils such as mink oil and lanolin; hydrocarbons such as liquid paraffin, squalane, and squalene; higher alcohols such as stearyl alcohol, isostearyl alcohol, and cetyl alcohol; ester oils such as isopropyl myristate, oleyl oleate, and neopentyl glycol dicaprate; ether oils such as ethylene glycol dioctyl ether; silicone oils such as dimethyl silicone oil, alcohol-modified silicone oil, alkyl-modified silicone oil, and amino-modified silicone oil; and fluorine oils such as perfluoropolyether.

[0065] The drug sheet 410 may further include a transmission sheet 420 made of a light-transmitting material. By using the transmission sheet 420, the light source unit 110 and the drug sheet 410 do not come into direct contact with each other, so that the light source unit 110 can be prevented from being soiled by the drug sheet 410. As such a light-transmitting material, the material used for the container 121 in FIG. 1 can be used.

[0066] As in the drug release device described with reference to Figures 1 and 3, a control unit (not shown) for controlling the irradiation of light from the light source unit 110 may be further provided. The control unit may control the irradiation of at least one light selected from the group consisting of the irradiation time, irradiation timing (number of irradiations), and light wavelength of the light from the light source unit 110. This allows control of the injection depth, administration time, etc.

[0067] Furthermore, the medicine supply unit 120 may be provided detachably with respect to the light source unit 110. This allows the medicine sheet 410 to be replaced.

[0068] Next, the mechanism of drug release using such a drug release device 400 will be described. The drug release device 400 in Fig. 4 is applied to the body surface, and light is emitted from the light source unit 110. As a result, the light is irradiated onto the medicinal ingredients in the drug sheet 410, and the medicinal ingredients absorb the light and are heated by molecular vibration. The heated medicinal ingredients diffuse from the body surface into the body. This allows the penetration effect of the medicinal ingredients to be enhanced compared to ordinary poultices.

[0069] Once the medicinal ingredients have diffused into the body and the vibrational energy is lost, the diffusion of the medicinal ingredients stops; however, by continuing to irradiate light from the light source unit 110, the medicinal ingredients in the drug sheet 410 are successively heated, and the diffusion energy is transmitted to the medicinal ingredients that have diffused into the body, making it possible for the medicinal ingredients to penetrate from the epidermis to the dermis.

[0070] In order to further diffuse the medicinal ingredients diffused in the body, the wavelength of the light from the light source unit 110 may be changed to a wavelength in the near-infrared region that penetrates the skin. This allows the medicinal ingredients diffused in the body to penetrate further into the body if they absorb wavelengths in the near-infrared region.

[0071] In addition, components other than the medicinal ingredients of the drug sheet 410 (moisturizing ingredients, water, water-soluble polymers, crosslinking agents, etc.) may be irradiated with light from the light source unit 110, absorbed, and heated by molecular vibration. Since the area around the medicinal ingredients is heated, the diffusion of the medicinal ingredients is assisted, and the diffusion of the medicinal ingredients from the body surface into the body may be promoted.

[0072] The magnitude of the diffused energy can be changed by changing the irradiation time and intensity of the light from the light source unit 110, and the penetration depth and penetration area into the body can be controlled. In addition, the irradiation time and wavelength of the light from the light source unit 110 may be changed and irradiation of a substance other than the medicinal ingredient may be appropriately combined.

[0073] In addition, by measuring the transmission and absorption spectrum of the above-mentioned drugs (medicinal ingredients and other ingredients), their absorption regions and transmission regions where absorption is avoided can be easily determined. In addition, by appropriately combining these, the light from the light source unit is absorbed by the medicinal ingredients, the medicinal ingredients are heated, and the medicinal ingredients can penetrate into the body. In addition, a person skilled in the art will understand that the absorption region or the window wavelength region where absorption is avoided can also be controlled by adjusting the derivatives of the medicinal ingredients or other ingredients. [Industrial Applicability]

[0074] The drug release device of the present invention reduces the burden on the patient and can be applied to the treatment of diabetic and pediatric patients. In addition, since it enables drug administration to deep inside the body using light, it is also effective in treating intractable cancers. In addition, since it allows administration to only a very limited area using light, damage to normal tissues can be minimized. Furthermore, by controlling the light irradiation time or the number of irradiations, the drug administration time and dosage can be automatically controlled and managed. [Explanation of symbols]

[0075] 100: Drug delivery device 110: Light source section 120: Drug Supply Department 121: Container 122: Drug permeable surface 130: Drugs 210: Body surface 220: light 230:Shock Wave 240: Cavitation bubbles 250: Molecular jet 300: Drug delivery device 310: Reservoir tank 320: Porous body 400: Drug delivery device 410:Medicine sheet 420:Transparent sheet

Claims

1. A light source unit; a medicine supply unit including a medicine to be irradiated with light from the light source unit; Equipped with The medicine supply unit further includes a medicine sheet containing the medicine and a light-transmitting sheet made of a material that transmits the light, The drug sheet is laminated to the permeable sheet, The drug supply unit is a drug discharging device that releases or ejects the drug by the light from the light source unit.

2. The drug delivery device according to claim 1 , wherein the light source unit is a laser or a light emitting diode.

3. The drug delivery device of claim 2, wherein the laser or light emitting diode is a tunable laser.

4. The light-transmitting material is a material selected from the group consisting of glass, quartz, and sapphire when the light has a wavelength in the visible light region, and is a material selected from the group consisting of germanium (Ge), silicon (Si), silicon carbide (SiC), calcium fluoride (CaF ２ ), barium fluoride (BaF ２ ), magnesium fluoride (MgF ２ ), thallium halide mixed crystal, lithium fluoride (LiF), silicon dioxide (SiO ２ 4. The drug release device according to claim 1, wherein the material is selected from the group consisting of zinc selenide (ZnSe).

5. The drug release device according to any one of claims 1 to 4, wherein the drug sheet contains a medicinal component selected from the group consisting of steroidal anti-inflammatory agents, non-steroidal anti-inflammatory agents, antiallergic agents, antihistamines, central nervous system agents, hormones, antihypertensive agents, cardiac stimulants, antiarrhythmic agents, coronary vasodilators, local anesthetics, analgesics, muscle relaxants, antifungal agents, anti-malignant tumor agents, urinary incontinence agents, antiepileptic agents, anti-Parkinson's agents, antiemetic agents, frequent urination agents, Ca antagonists, psychotropic drugs, antidizziness agents, cardiovascular system drugs, antitussives and expectorants, cerebral circulation improving agents, cerebrovascular dementia agents, Alzheimer's therapeutic agents, polypeptide hormone agents, immunomodulators, choleretic agents, diuretics, diabetes mellitus agents, gout therapeutic agents, smoking cessation aids, vitamins, prostaglandins, stimulants, hypnotics and sedatives, autonomic nerve agents, and peripheral vasodilators.

6. The drug release device according to claim 5 , wherein the light source unit emits light having photon energy that excites the medicinal component.

7. The drug release device according to any one of claims 1 to 6, further comprising a control unit for controlling the emission of light from the light source unit.

8. The drug release device according to claim 7 , wherein the control unit controls at least one light irradiation selected from the group consisting of an irradiation time of the light, an irradiation timing of the light, and a wavelength of the light.

9. The drug discharging device according to any one of claims 1 to 8, wherein the drug supplying section is provided detachably with respect to the light source section.

10. 7. The drug releasing device according to claim 5, wherein the drug sheet further contains at least one of a moisturizing component, water, a water-soluble polymer, and a crosslinking agent in addition to the medicinal component.

Images